>
ConvaTec logo

CTEC - ConvaTec Share Price

206.9p 1.0  0.5%

Last Trade - 22/04/21

Sector
Healthcare
Size
Large Cap
Market Cap Ā£4.13bn
Enterprise Value Ā£4.83bn
Revenue Ā£1.36bn
Position in Universe 208th / 1821
Bullish
Bearish
Unlock CTEC Revenue
Momentum
Relative Strength (%)
1m +3.30%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.41%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1,650 1,688 1,765 1,832 1,827 1,894 1,979 2,057 +2.8%
+17.9 -30.6 -10.4 +81.2 +15.9
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ConvaTecGroup PLC revenues increased 4% to $1.89B. Net incomeincreased from $9.8M to $112.5M. Revenues reflect Denmarksegment increase of 16% to $316.1M, U.S segment increase of3% to $666.1M. Net income benefited from Interest expenseon borrowings decrease of 35% to $39.2M (expense),Amortisation of deferred financing fees decrease of 66% to$5.9M (expense). Dividend per share remained flat at $0.06.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CTEC
Graphical History

Revenue

CTEC Revenue Unlock CTEC Revenue

Net Income

CTEC Net Income Unlock CTEC Revenue

Normalised EPS

CTEC Normalised EPS Unlock CTEC Revenue

PE Ratio Range

CTEC PE Ratio Range Unlock CTEC Revenue

Dividend Yield Range

CTEC Dividend Yield Range Unlock CTEC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CTEC EPS Forecasts Unlock CTEC Revenue
Profile Summary

ConvaTec Group PLC is a United Kingdom-based medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. It operates across market franchises, such as Advanced Wound Care, which provides advanced wound dressings and skin care products; Ostomy Care, which provides devices, accessories and services for people with a stoma, resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity and other causes; Continence and Critical Care, which provides products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida and other causes, and Infusion Devices, which provide disposable infusion sets.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated September 6, 2016
Public Since October 26, 2016
No. of Shareholders: n/a
No. of Employees: 9,689
CTEC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CTEC
Upcoming Events for CTEC
Thursday 29th April, 2021
Q1 2021 ConvaTec Group PLC Trading Statement Release
Friday 7th May, 2021
ConvaTec Group PLC Annual Shareholders Meeting
Friday 7th May, 2021 Estimate
ConvaTec Group PLC Annual Shareholders Meeting
Wednesday 4th August, 2021 Estimate
Half Year 2021 ConvaTec Group PLC Earnings Release
Frequently Asked Questions for ConvaTec
What is the ConvaTec share price?

As of 22/04/21, shares in ConvaTec are trading at 206.9p, giving the company a market capitalisation of Ā£4.13bn. This share price information is delayed by 15 minutes.

How has the ConvaTec share price performed this year?

Shares in ConvaTec are currently trading at 206.9p and the price has moved by 11.3% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ConvaTec price has moved by -9.9% over the past year.

What are the analyst and broker recommendations for ConvaTec?

Of the analysts with advisory recommendations for ConvaTec, there are there are currently 3 "buy" , 6 "hold" and 1 "sell" recommendations. The overall consensus recommendation for ConvaTec is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will ConvaTec next release its financial results?

ConvaTec is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the ConvaTec dividend yield?

The ConvaTec dividend yield is 1.98% based on the trailing twelve month period.

Does ConvaTec pay a dividend?

Last year, ConvaTec paid a total dividend of 0.06, and it currently has a trailing dividend yield of 1.98%. Looking ahead, ConvaTec has not announced an ex-dividend date yet and the next dividend pay date is 2021-05-13.

When does ConvaTec next pay dividends?

ConvaTec has yet to annouce their ex-dividend date and the next dividend pay date is 2021-05-13. The historic dividend yield on ConvaTec shares is currently 1.98%.

How do I buy ConvaTec shares?

To buy shares in ConvaTec you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopediaā€™s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ConvaTec?

Shares in ConvaTec are currently trading at 206.9p, giving the company a market capitalisation of Ā£4.13bn.

Where are ConvaTec shares listed? Where are ConvaTec shares listed?

Here are the trading details for ConvaTec:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: CTEC
What kind of share is ConvaTec?

Based on an overall assessment of its quality, value and momentum, ConvaTec is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ConvaTec share price forecast 2021?

Shares in ConvaTec are currently priced at 206.9p. At that level they are trading at 6.35% discount to the analyst consensus target price of 220.93.

Analysts covering ConvaTec currently have a consensus Earnings Per Share (EPS) forecast of 0.126 for the next financial year.

How can I tell whether the ConvaTec share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ConvaTec. Over the past six months, the relative strength of its shares against the market has been -7.58%. At the current price of 206.9p, shares in ConvaTec are trading at 5.22% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ConvaTec PE Ratio?

The ConvaTec PE ratio based on its reported earnings over the past 12 months is 41.25. The shares are currently trading at 206.9p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of ConvaTec?

ConvaTec's management team is headed by:

Rick Anderson - NID
John Lindskog - CEX
Adam Deutsch - EVP
Frank Schulkes - CFO
Regina Benjamin - NID
Margaret Ewing - NID
Kjersti Grimsrud - CEX
Sten Scheibye - NED
Karim Bitar - CEO
David Shepherda - CEX
Supratim Bose - CEX
John McAdam - NEC
Seth Segel - CEX
Mani Gopal - CEX
Natalia Kozmina - CHO
Who are the major shareholders of ConvaTec?

Here are the top five shareholders of ConvaTec based on the size of their shareholding:

Novo Nordisk Foundation Corporation
Percentage owned: 19.72% (395.3m shares)
Artisan Partners Limited Partnership Investment Advisor
Percentage owned: 4.89% (98.0m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 4.86% (97.4m shares)
Black Creek Investment Management, Inc. Investment Advisor
Percentage owned: 3.99% (80.0m shares)
Jupiter Asset Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 3.55% (71.1m shares)
Similar to CTEC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.